肿瘤血液标志物的研发及临床评价课件.pptx

肿瘤血液标志物的研发及临床评价?;Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths by Sex, United States, 2013;Nature Reviews Cancer, 2011, 426-437;Outline of strategies for biomarker discovery through utilization of emerging technologies.;Cancer biomarkers that are currently in clinical use;;Multi-parameter panels can significantly improve the diagnostic value compared to the conventional biomarker ;8; A. 6例早期原发性肝癌和6例健康对照的全基因组甲基化水平。 B. 早期原发性肝癌组和健康对照组全基因组甲基化水平比较;? 与健康对照组相比，早期原发性肝癌组差异甲基化位点的个数及倍数关系;与健康对照组相比，早期原发性肝癌组差异甲基化位点的基因分布;β值大于0.5为超甲基化 β值小于0.2为超低甲基化 我们筛选出453个健康对照组和37个原发性肝细胞癌组的超甲基化位点。;超甲基化位点的基因本体论和基因功能富集分析; 原发性肝细胞癌组中超甲基化位点的GO及功能富集分析; 健康对照组中超甲基化位点的GO及功能富集分析; 基因功能富集分析后健康对照组中超甲基化位点的基因相互作用分析;DBX2和THY1甲基化位点通过亚硫酸盐测序法验证;DBX2和THY1甲基化位点通过亚硫酸盐测序法进行扩大样本验证 A. DBX2和THY1甲基化位点在原发性肝癌组和健康对照组的甲基化水平比较。B. DBX2和THY1甲基化位点用于区分原发性肝癌组和健康对照组的诊断价值;Multi-parameter model for diagnosis of cancer;29例慢性胰腺炎 82例急性胰腺炎 162例胰腺癌 33例结肠炎 62例结肠息肉 101例结肠癌 20例结肠癌术后 40例胃增生 139例胃癌 31例慢性肺炎 28例小细胞肺癌 32例肺鳞癌 72例肺腺癌 22例乳腺增生 101例乳腺癌 65例宫颈良性病变 72例宫颈癌 18例宫颈癌术后 84例前列腺增生 108例前列腺癌 12例前列腺癌术后 200例健康对照;For differentiating between the colorectal adenoma and colorectal cancer groups. The AUC of multivariate logistic regression was 0.945 (95% CI: 0.909–0.981). Compared with the conventional biomarkers CEA and CA199, the AUC of multivariate logistic regression showed significant improvements (p 0.05). AUC: Area under the curve. ;26;Figure 1. Flowchart of our experimental design;Table 1. Clinical characteristic of the studied subjects;Table 2. List of the serum parameters in the 61-plex panel;Table 3. The sensitivity of top 20 performing 4 serum parameter panels for discriminating PDAC Vs Control and PDAC Vs Benign group identified by MMC algorithm applied to the training set at 90% specificity;Figure 2. ROC curves analysis for discriminating between the PDAC versus Control and PDAC versus Benign groups in the training group. ROC curves of CA19-9, ALB, CRP and IL-8 panel (solid line) and CA19